The Laboratory Corporation of America Holdings (NYSE:LH), commonly known as Labcorp, has made significant strides in bio-tech market as shown by its financial performance, dividend policies, acquisitions, and product introductions. It announced dividends of $0.72, added FDA-authorized liquid biopsy tests to its oncology portfolio, and expanded its precision oncology portfolio with the addition of self-collection tests for HPV and STIs. LabCorp's Q4 sales and full-year outlook exceeded expectations. The company also announced victories in the form of acquisitions of select assets of BioReference Health's innovative oncology and clinical testing businesses, and of Invitae. Furthermore, Labcorp's stock witnessed robust growth reaching a 52-week high at $248.69. The company's CFO Glenn Eisenberg announced his plans for retirement with further restructuring in the organization expected. Looking forward, Labcorp has shown potential with its roll out of nationwide private self-collection options for HPV testing, and its anticipated growth as a result of increased diagnostics test demand.
Laboratory Corporation of America Holdings LH News Analytics from Sun, 19 Apr 2020 07:00:00 GMT to Thu, 24 Apr 2025 18:45:22 GMT -
